Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002052113-25-001535
Filing Date
2025-04-24
Accepted
2025-04-24 08:48:41
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5644
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2796
3 EXHIBIT 99: ITEM 7 Item_7.txt EX-99 437
  Complete submission text file 0002052113-25-001535.txt   10837
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Subject) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-42290 | Film No.: 25863814
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)